Treatment aspects for reducing the carbon dioxide content in the blood

US11904083B2 · kind B2 · utility

Assignee

• Fresenius Medical Care Deutschland GmbH · DE

Inventors

• Petra Abel · Friedberg, DE
• Jürgen Klewinghaus · Oberursel, DE
• Rolf Zander · Mainz, DE

Key dates

• Filing date: Dec 21, 2018
• Grant date: Feb 20, 2024
• Expiry date: Dec 12, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61M2205/3331
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to various aspects of a procedure for reducing the carbon dioxide content in blood during the treatment of patients. A first aspect of the present disclosure relates to a buffer solution for use in reducing the carbon dioxide content in the blood when treating a patient suffering from pulmonary insufficiency or the complete failure of lung function, wherein the fluid is in gas exchange with a portion of the patient's blood conducted through an extracorporeal circuit. The first aspect of the present disclosure further relates to an apparatus for the extracorporeal reduction of the carbon dioxide content in the blood using said buffer solution. A second aspect of the present disclosure relates to a system for extracorporeal blood treatment, likewise using said buffer solution and the apparatus, and furthermore to a treatment apparatus for extracorporeal blood treatment comprising the aforementioned system. A third aspect of the present disclosure relates to a functional unit for performing extracorporeal blood treatment, a blood-guiding apparatus for interacting with the functional unit for performing an extracorporeal blood treatment using the aforemen…